The Global Asthma Network rationale and methods for Phase I global surveillance: prevalence, severity, management and risk factors
The Global Asthma Network rationale and methods for Phase I global surveillance: prevalence, severity, management and risk factors
复制标题
DOI：
10.1183/13993003.01605-2016
复制
发表时间：
2017-01-01
影响因子：
24.3
通讯作者：
Strachan, David P.
中科院分区：
文献类型：
--
作者：
Ellwood, Philippa;Asher, M. Innes;Strachan, David P.
全球哮喘网络 (GAN) 继国际儿童哮喘和过敏研究 (ISAAC) 后于 2012 年成立。 ISAAC 第一阶段涉及来自 56 个国家 156 个中心的 700 000 多名青少年和儿童；研究发现，全球范围内哮喘、鼻炎和湿疹的症状患病率存在显着差异，而目前对这些疾病的了解无法解释这一差异； ISAAC 第三阶段涉及超过 1,187,496 名青少年和儿童（98 个国家的 237 个中心）。研究发现，哮喘症状患病率在许多地方都在增加，特别是在严重程度也很高的低收入和中等收入国家，并确定了一些需要进一步调查的环境因素。本文中描述的 GAN 第一阶段以 ISAAC 调查结果为基础，收集有关哮喘、鼻炎和湿疹患病率、严重程度、诊断、哮喘急诊室就诊、入院、哮喘基本药物的管理和使用的更多信息。受试者的年龄组与 ISAAC 及其父母相同。自 2003 年以来首次对儿童和成人哮喘进行全球监测，将获得进一步的证据来了解哮喘、管理实践和危险因素，从而进一步认识到哮喘是一种重要的非传染性疾病，并减轻其全球负担。
The Global Asthma Network (GAN), established in 2012, followed the International Study of Asthma and Allergies in Childhood (ISAAC). ISAAC Phase One involved over 700 000 adolescents and children from 156 centres in 56 countries; it found marked worldwide variation in symptom prevalence of asthma, rhinitis and eczema that was not explained by the current understanding of these diseases; ISAAC Phase Three involved over 1 187 496 adolescents and children (237 centres in 98 countries). It found that asthma symptom prevalence was increasing in many locations especially in low-and middle-income countries where severity was also high, and identified several environmental factors that required further investigation.GAN Phase I, described in this article, builds on the ISAAC findings by collecting further information on asthma, rhinitis and eczema prevalence, severity, diagnoses, asthma emergency room visits, hospital admissions, management and use of asthma essential medicines. The subjects will be the same age groups as ISAAC, and their parents. In this first global monitoring of asthma in children and adults since 2003, further evidence will be obtained to understand asthma, management practices and risk factors, leading to further recognition that asthma is an important non-communicable disease and to reduce its global burden.